Inhibikase Therapeutics Stock Drops After Follow-On Equity Offering Of $45M Issued At 26% Discount

  • Inhibikase Therapeutics Inc IKT has priced an underwritten public offering of 15 million shares at $3/share for gross proceeds of approximately $45 million.
  • The offer price represents a 26% discount on the last close price of $4.03 on Tuesday.
  • Underwriters have an option to purchase up to 2.25 million additional shares.
  • The offering will close by June 18.
  • The company will use the proceeds to fund the Phase 2 efficacy trial and Phase 1b extension study for IkT-148009 in Parkinson's, production of IkT-148009 for Phase 1b and Phase 2 studies.
  • ThinkEquity, a Fordham Financial Management division, is acting as the sole book-running manager for the offering. JonesTrading Institutional Services LLC is acting as the co-manager for the offering.
  • In February, the first patients were dosed in a Phase 1 trial of IkT-148009.
  • In December 2020, the company raised $18 million after closing its IPO.
  • Price Action: IKT shares are down 24.9% at $3.03 during the premarket session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPenny StocksHealth CareOfferingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!